{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:47:34Z","timestamp":1790524054392,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Catabasis Pharmaceuticals","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100005693","name":"Parent Project Muscular Dystrophy","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-019-1304-8","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T17:06:53Z","timestamp":1556816813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry"],"prefix":"10.1186","volume":"19","author":[{"given":"Leslie","family":"Cowen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"1304_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AE Emery","year":"2002","unstructured":"Emery AE. The muscular dystrophies. Lancet. 2002;359:687\u201395.","journal-title":"Lancet"},{"key":"1304_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","volume":"82","author":"DJ Blake","year":"2002","unstructured":"Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291\u2013329.","journal-title":"Physiol Rev"},{"key":"1304_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79.","journal-title":"Orphanet J Rare Dis"},{"key":"1304_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin. 2014;32:671\u201388 viii.","journal-title":"Neurol Clin"},{"key":"1304_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/01.wnl.0000173836.09176.c4","volume":"65","author":"YW Chen","year":"2005","unstructured":"Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 2005;65:826\u201334.","journal-title":"Neurology"},{"key":"1304_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1474-4422(18)30115-7","volume":"17","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Mercuri E. Evidence-based care in Duchenne muscular dystrophy. Lancet Neurol. 2018;17:389\u201391.","journal-title":"Lancet Neurol"},{"key":"1304_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391:451\u201361.","journal-title":"Lancet"},{"key":"1304_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/jnnp.2007.141721","volume":"80","author":"M Kohler","year":"2009","unstructured":"Kohler M, Clarenbach CF, Bahler C, Brack T, Russi EW, Bloch KE. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2009;80:320\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1304_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","volume":"56","author":"P Kieny","year":"2013","unstructured":"Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper Centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56:443\u201354.","journal-title":"Ann Phys Rehabil Med"},{"key":"1304_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79:257\u201371.","journal-title":"Ann Neurol"},{"key":"1304_CR11","doi-asserted-by":"crossref","unstructured":"Gloss D, Moxley RT, 3rd, Ashwal S, and Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development Subcommittee of the American Academy of neurology. Neurology 2016;86:465\u2013472.","DOI":"10.1212\/WNL.0000000000002337"},{"key":"1304_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology. 2015;85:1048\u201355.","journal-title":"Neurology"},{"key":"1304_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"EK Henricson","year":"2013","unstructured":"Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve. 2013;48:55\u201367.","journal-title":"Muscle Nerve"},{"key":"1304_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpeds.2016.11.078","volume":"182","author":"BL Wong","year":"2017","unstructured":"Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, et al. Long-term outcome of interdisciplinary Management of Patients with Duchenne muscular dystrophy receiving daily glucocorticoid treatment. J Pediatr. 2017;182:296\u2013303.e1.","journal-title":"J Pediatr"},{"key":"1304_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393.","journal-title":"Lancet Neurol"},{"key":"1304_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.nmd.2017.05.012","volume":"28","author":"LM Ward","year":"2018","unstructured":"Ward LM, Kinnett K, Bonewald L. Proceedings of a Parent Project Muscular Dystrophy bone health workshop: morbidity due to osteoporosis in DMD: the Path forward may 12-13, 2016, Bethesda, Maryland, USA. Neuromuscul Disord. 2018;28:64\u201376.","journal-title":"Neuromuscul Disord"},{"key":"1304_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrrheum.2012.85","volume":"8","author":"BY Hanaoka","year":"2012","unstructured":"Hanaoka BY, Peterson CA, Horbinski C, Crofford LJ. Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2012;8:448\u201357.","journal-title":"Nat Rev Rheumatol"},{"key":"1304_CR18","doi-asserted-by":"crossref","unstructured":"Schakman O, Gilson H, Kalista S, Thissen J. Mechanisms of muscle atrophy induced by glucocorticoids. Hormone Res. 72(Suppl 1):36\u201341.","DOI":"10.1159\/000229762"},{"key":"1304_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367.","journal-title":"Lancet Neurol"},{"key":"1304_CR20","first-page":"1110","volume":"317","author":"R Voelker","year":"2017","unstructured":"Voelker R. First corticosteroid approved for Duchenne muscular dystrophy. Jama. 2017;317:1110.","journal-title":"Jama"},{"key":"1304_CR21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123\u201331.","journal-title":"Neurology"},{"key":"1304_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/mus.26191","volume":"58","author":"PB Shieh","year":"2018","unstructured":"Shieh PB, McIntosh J, Jin F, Souza M, Elfring G, Narayanan S, et al. Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: a post HOC analysis from the ACT DMD trial. Muscle Nerve. 2018;58:639\u201345.","journal-title":"Muscle Nerve"},{"key":"1304_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","volume":"58","author":"M Guglieri","year":"2017","unstructured":"Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, et al. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemp Clin Trials. 2017;58:34\u20139.","journal-title":"Contemp Clin Trials"},{"key":"1304_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mus.23831","volume":"48","author":"RC Griggs","year":"2013","unstructured":"Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve. 2013;48:27\u201331.","journal-title":"Muscle Nerve"},{"key":"1304_CR25","doi-asserted-by":"publisher","first-page":"RRN1309","DOI":"10.1371\/currents.RRN1309","volume":"4","author":"V Rangel","year":"2012","unstructured":"Rangel V, Martin AS, Peay HL. DuchenneConnect registry report. PLoS Curr. 2012;4:RRN1309.","journal-title":"PLoS Curr"},{"key":"1304_CR26","doi-asserted-by":"crossref","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016:Cd003725.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"1304_CR27","doi-asserted-by":"publisher","unstructured":"Kinnett K, Noritz G. The PJ Nicholoff steroid protocol for Duchenne and Becker muscular dystrophy and adrenal suppression. PLoS Curr. 2017;9. \n                    https:\/\/doi.org\/10.1371\/currents.md.d18deef7dac96ed135e0dc8739917b6e\n                    \n                  .","DOI":"10.1371\/currents.md.d18deef7dac96ed135e0dc8739917b6e"},{"key":"1304_CR28","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/08830738010160111406","volume":"16","author":"SD Johnsen","year":"2001","unstructured":"Johnsen SD. Prednisone therapy in Becker\u2019s muscular dystrophy. J Child Neurol. 2001;16:870\u20131.","journal-title":"J Child Neurol"},{"key":"1304_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1536\/ihj.16-044","volume":"57","author":"M Nakamura","year":"2016","unstructured":"Nakamura M, Sunagawa O, Hokama R, Tsuchiya H, Miyara T, Taba Y, et al. A Case of refractory heart failure in Becker muscular dystrophy improved with corticosteroid therapy. Int Heart J. 2016;57:640\u20134.","journal-title":"Int Heart J"},{"key":"1304_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","volume":"16","author":"WD Biggar","year":"2006","unstructured":"Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16:249\u201355.","journal-title":"Neuromuscul Disord"},{"key":"1304_CR31","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","volume":"68","author":"WM King","year":"2007","unstructured":"King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68:1607\u201313.","journal-title":"Neurology"},{"key":"1304_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/0883073813517263","volume":"30","author":"DJ Fox","year":"2015","unstructured":"Fox DJ, Kumar A, West NA, DiRienzo AG, James KA, Oleszek J. Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982-2001. J Child Neurol. 2015;30:21\u20136.","journal-title":"J Child Neurol"},{"key":"1304_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, et al. The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48:32\u201354.","journal-title":"Muscle Nerve"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1304-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T23:18:17Z","timestamp":1588288697000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1304-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1304"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1304-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent from participants or their parents\/guardians was obtained in compliance with all local laws and regulations, and institutional investigational review board or ethics committee approval. The Duchenne Registry and electronic consent are approved by the Geisinger Institutional Review Board (Geisinger Medical Center, Danville, PA, IRB#2014\u20130621).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LC, MM and JD are employees of Catabasis Pharmaceuticals, the study sponsor, which is developing an investigational drug, edasalonexent, for treatment of Duchenne muscular dystrophy, which is being studied in patients not on corticosteroids.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"84"}}